People

Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.

Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.

As it continues to build on the biosimilars business gained from a major transaction with former partner Viatris, Biocon Biologics has announced a raft of executive appointments to bolster its management team.

After a tough 2022 for its generics business, Hikma is predicting big things for the division this year, raising its full-year guidance from 20% growth to nearly 30% as new CEO Riad Mishlawi prepares to take the reins from the start of September. Meanwhile, the firm has also picked up assets from Akorn following its collapse.

Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, according to an investment banker.

Teva has named a new executive vice president in charge of business development for the off-patent industry giant. At the same time, biosimilars specialist Henlius has appointed a fresh CEO, Coherus has added a new director and Olon has recruited a biotech chief.

Stada has named new leaders for the UK and the Eastern Europe region. Meanwhile, French industry association Gemme has elected a fresh president and a new executive has joined Civica.

Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.

Perrigo has named its new leader after Murray Kessler last month announced plans to retire. Patrick Lockwood-Taylor will bring his OTC brand background to the consumer healthcare specialist as president and CEO from 30 June.

Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.

UK generics and biosimilars industry association the BGMA is laying the groundwork for new leadership after appointing Sandoz UK head Diane DiGangi Trench as its vice-chair, ahead of her moving up to chair next year.

As Sandoz moves closer to being spun off from parent company Novartis, the generics and biosimilars firm has revealed the structure and membership of its board under chair Gilbert Ghostine.

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

Six months after replacing its chief quality officer, biosimilars specialist Alvotech has again appointed a new head of quality, in the wake of the latest US FDA knockback for its AVT02 proposed adalimumab biosimilar rival to Humira.

Zentiva has announced that Steffen Saltofte will become CEO of the privately-owned generics firm, replacing Nick Haggar who has led the company for over four years.

The IGBA has named the AAM’s David Gaugh as its chair for the remained of 2023, following the recent departure of Jonathan Kimball. At the same time, the international generics and biosimilars association has added two recently-appointed off-patent industry CEOs to its advisory committee, representing Apotex And Viatris.